Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Poolbeg PharmaPOLBF +0.84% 12-1 Month Momentum % is 123.53% as of Aug. 02, 2026. The stock has 1 warning sign investors should review. Among 1,359 Biotechnology companies, Poolbeg Pharma ranks better than 91.17% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-02), Poolbeg Pharma's 12-1 Month Momentum % is 123.53%.
The industry rank for Poolbeg Pharma's 12-1 Month Momentum % or its related term are showing as below:
POLBF's 12-1 Month Momentum % is ranked better than 91.17% of 1359
companies
in the Biotechnology industry
Industry Median: -16.89
vs POLBF: 123.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Poolbeg Pharma 12-1 Month Momentum % Related Terms
POLBF vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Poolbeg Pharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 123.53% mean?
Poolbeg Pharma (POLBF) has a 12-1 Month Momentum % of 123.53% as of Aug. 02, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #120 out of 1359 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Poolbeg Pharma's 12-1 Month Momentum % too high?
Poolbeg Pharma's current 12-1 Month Momentum % is 123.53%. Based on the distribution chart, Poolbeg Pharma ranks #120 out of 1359 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Poolbeg Pharma's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #120 out of 1359 companies for 12-1 Month Momentum %. This places Poolbeg Pharma in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current 12-1 Month Momentum % is 123.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current 12-1 Month Momentum % of 123.53%. The current 12-1 Month Momentum % is 123.53%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current 12-1 Month Momentum % is 123.53% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 
